Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2026 17:00 ET | Source: Senseonics Holdings, Inc.

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance New data expands on findings...
June 05, 2026 19:32 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
June 05, 2026 19:32 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...
June 05, 2026 16:45 ET | Source: Zealand Pharma

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity

Press release – No. 13 / 2026 New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...
June 05, 2026 15:45 ET | Source: Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific Sessions

Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, Featured in Oral Presentation Today at ADA 2026 Scientific Sessions
June 04, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...
June 03, 2026 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking...
June 03, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...
June 03, 2026 03:30 ET | Source: SNS Insider pvt ltd

Photomask Market Size to Grow USD 8.19 Billion by 2035 | Research by SNS Insider

Global Photomask Market Size, Share, Trends & Segment Analysis by Product, Application, Technology, End Use, Region & Forecast 2026-2035
June 01, 2026 08:00 ET | Source: Senseonics Holdings, Inc.

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of...